Metastatic Triple Negative Breast Cancer Clinical Trials 2023

What are the top hospitals conducting metastatic triple negative breast cancer research?

When it comes to cutting-edge clinical trials for metastatic triple negative breast cancer, some of the top hospitals in the United States are making significant strides. In Boston's medical landscape, Massachusetts General Hospital leads the way with nine active trials focused specifically on this aggressive form of breast cancer. With a history of 34 completed trials in metastatic triple negative breast cancer and their first recorded trial dating back to 2011. Right beside them is Dana-Farber Cancer Institute, also located in Boston, actively conducting eight innovative clinical trials for this condition. They have an impressive track record as well, having already completed 33 studies since initiating their first trial in 2010.

Meanwhile, Memorial Sloan Kettering Cancer Center in New york City stands out with its seven ongoing metastatic triple negative breast cancer trials and a total of 38 successful past studies conducted since recording their inaugural trial in 2011. Additionally adding itself to this list is M D Anderson Cancer Center situated in Houston which currently conducts six active clinical tests while it holds eighteen completed investigations from starting pioneering investigation around ten years ago until2012.Beth Israel Deaconess Medical Center rounds off the list with six current metastatic triple negative breast cancer trials and a commendable tally of eighteen previous studies dating back to their initial recorded trial conducted in 2010.

These esteemed institutions are at the forefront of advancing knowledge and treatment options for those affected by metastatic triple-negative breast cancer—a subtype known for its lack of hormone receptors and high rates of recurrence. Through these dedicated efforts across multiple locations, researchers aim to improve survival rates and enhance quality-of-life outcomes for patients battling this challenging disease.

Which are the best cities for metastatic triple negative breast cancer clinical trials?

Boston, Massachusetts; Houston, Texas; New york, New York; Nashville, Tennessee; and Chicago, Illinois emerge as the top cities for metastatic triple negative breast cancer clinical trials. These cities offer a significant number of active trials focused on finding effective treatments for this challenging subtype. With 44 ongoing studies in Boston alone investigating medications like Pembrolizumab and Cediranib Maleate among others, it serves as a prime location for trial participation. Houston follows closely with 40 trials exploring therapies such as Atezolizumab and Technetium Tc-99m Sestamibi. Meanwhile, both New York and Nashville each have 40+ active trials that investigate various treatment options including BMS-986340 and DF6002 respectively. Additionally, Chicago presents promising opportunities through its 27 ongoing studies targeting triple negative breast cancer with drugs like TAK-676. These cities pave the way towards advancements in care for individuals battling metastatic triple negative breast cancer.

Which are the top treatments for metastatic triple negative breast cancer being explored in clinical trials?

Metastatic triple negative breast cancer is a challenging form of the disease, but there are several promising treatments being explored in clinical trials. Leading the way is pembrolizumab, which is currently being tested in 17 active trials and has been involved in 82 all-time metastatic triple negative breast cancer studies since its introduction in 2015. Another contender on the list is atezolizumab, with four ongoing trials and 27 all-time studies dedicated to this aggressive subtype of breast cancer since also making its debut in 2015. Enzalutamide follows closely behind, participating in two active trials and contributing to five all-time metastatic triple negative breast cancer research projects after entering the scene back in 2013. In addition to these established treatments, newer options like NUV-868 and SGN-B7H4V are beginning their journey towards finding potential breakthroughs for patients with metastatic triple negative breast cancer through their respective ongoing clinical trials initiated just last year (2022). The quest for advancements continues as researchers strive to improve outcomes for individuals affected by this formidable condition.

What are the most recent clinical trials for metastatic triple negative breast cancer?

Exciting advancements are being made in the field of metastatic triple negative breast cancer, with recent clinical trials offering promising potential for improved treatments. A Phase 2 trial is investigating the efficacy of a therapy specifically designed for tumors larger than 5 cm, aiming to provide valuable insights into managing this subtype of metastatic triple negative breast cancer. Another Phase 2 trial explores an innovative anti-HER2/HER3 dendritic cell vaccine, which holds great promise as a targeted treatment option. Additionally, ongoing Phase 1 trials are evaluating the effectiveness of SGN-PDL1V and NUV-868 in treating metastatic triple negative breast cancer. These studies bring us closer to more personalized approaches that can significantly impact patient outcomes.

What metastatic triple negative breast cancer clinical trials were recently completed?

Multiple clinical trials investigating treatments for metastatic triple negative breast cancer have recently concluded, showcasing ongoing efforts to combat this challenging disease. In November 2021, G1 Therapeutics successfully completed a trial evaluating the potential of Trilaciclib. Similarly, VelosBio Inc. wrapped up their study on Zilovertamab vedotin in October 2020. Another significant milestone was reached in September 2020 with the completion of Hoffmann-La Roche's Tiragolumab trial. These advancements highlight the dedication and progress being made in developing new therapies for metastatic triple negative breast cancer patients.